VRTX — Vertex Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $114.69bn
- $108.40bn
- $11.02bn
- 100
- 29
- 80
- 80
Annual cashflow statement for Vertex Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 2,712 | 2,342 | 3,322 | 3,620 | -536 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 209 | 436 | 595 | 539 | 699 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -54.5 | -105 | 341 | -266 | -515 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 3,254 | 2,644 | 4,130 | 3,537 | -493 |
| Capital Expenditures | -260 | -235 | -205 | -258 | -485 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 359 | -106 | -116 | -2,883 | -3,285 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 99.4 | -341 | -321 | -3,142 | -3,770 |
| Financing Cash Flow Items | -202 | -130 | -169 | -226 | -399 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -505 | -1,478 | -67.7 | -562 | -1,495 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2,868 | 811 | 3,712 | -140 | -5,800 |